Large randomised trials and meta-analyses of breast cancer treatments
Lead Research Organisation:
Medical Research Council
Abstract
This programme undertakes research to improve the treatment and survival of women with breast cancer by undertaking randomised controlled trials of new and existing treatments and systematically collecting and analysing the data from all breast cancer trials undertaken worldwide. This collaboration meets every few years and involves around 600 trialists. The published findings have had a major impact on cancer research, resulting in new trials to address important treatment questions that had yet to be reliably addressed. An example of such a trial is the ongoing ATLAS trial, which is run from CTSU and involves more than a 1,000 collaborating doctors in 38 countries, has randomised 13,000 women to either 5 or 10 years treatment with tamoxifen, and has shown that longer treatment improves 15 year survival. The published research findings of the collaboration have also had a major impact on the treatment of breast cancer. It has been referenced in evidence-based guidelines worldwide, including those published by the UK National Institute of Clinical Excellence, NICE. While the long-term survival gains identified from the research of the collaboration are each only moderate, the combination of several of these moderate gains have resulted in a halving of breast cancer mortality in the UK for women aged 35-69.
Technical Summary
The programme will continue the long-running Early Breast Cancer Triallists’ Collaborative Group (EBCTCG) and the ATLAS trial follow-up to obtain large-scale randomised evidence about the long-term main effects and side-effects of local and systemic adjuvant breast cancer treatments, and influence the interpretation of past trials and the design of future trials of treatment and screening. About every 5 years, EBCTCG seeks data on each individual patients in all adjuvant breast trials, for checking and meta-analyses and has previously demonstrated effects on mortality not reliably demonstrable in separate trials. EBCTGCG reports (>14,000 citations) influence practice guidelines and change worldwide treatment patterns. The long-term survival gains identified are each only moderate, but, from the combination of several moderate gains, UK breast cancer mortality at age 35-69 has been halved. The collaboration has also shown that 5-year tamoxifen reduces 10-year and 15-year breast cancer mortality rates by 1/3. It was feared that continuing tamoxifen for more than 5 years might increase rather than decrease recurrence, but CTSU’s ATLAS trial (n=13,000) randomised 10-year vs 5-year tamoxifen and showed 10-year continuation moderately lowers 15-year mortality. Follow-up of ATLAS is continuing, as ER+ disease can recur throughout years 10-20.
Organisations
- Medical Research Council (Lead Research Organisation)
- University of Hasselt, Belgium (Collaboration)
- University of Edinburgh, United Kingdom (Collaboration)
- Hospital Dipreca (Collaboration)
- Hospital Comarcal de Blanes (Collaboration)
- Gertsen Moscow Research Oncology Institute (Collaboration)
- Hospital Civil de Guadalajara (HCG) (Collaboration)
- UNLISTED (Collaboration)
- Comprehensive Cancer Centre Integral Cancer Center Netherlands (Collaboration)
- Maria Curie Provincial Teaching Cancer Hospital (Collaboration)
- Translational Research in Oncology (TRIO) (Collaboration)
- Hospital Amstelland (Collaboration)
- Podkarpackie Oncology Center (Collaboration)
- Hospital del Salvador (Collaboration)
- Rosario Oncology Centre (Collaboration)
- Jiangxi Province Cancer Hospital (Collaboration)
- Hospital Escuela Eva Perón (Collaboration)
- Gunma University (Collaboration)
- The Hospital of St. Leopoldo Mandic (Collaboration)
- Dana-Farber Cancer Institute (Collaboration)
- Santa Casa de Misericordia, Passos (Collaboration)
- Hospital Universitario De La Princesa (Collaboration)
- Inner Mongolia Medical College Hospital (Collaboration)
- Las Higueras Hospital (Collaboration)
- Hospital Napoleão Laureano, Joao Pessoa (Collaboration)
- Austrian Breast & Colorectal Cancer Study Group (Collaboration)
- Shohada Hospital (Collaboration)
- University Hospital Motol (Collaboration)
- Madras Cancer Institute (WIA), Chennai (Collaboration)
- University College London, United Kingdom (Collaboration)
- Edith Wolfson Medical Center (Collaboration)
- State university of Santa Cruz (Collaboration)
- Central Oncology Group (Collaboration)
- Westmead Hospital (Collaboration)
- South-Eastern Cancer Study Group and Alabama Breast Cancer Project (Collaboration)
- Hospital General San Jorge of Huesca (Collaboration)
- Pontifical Catholic University of Chile (Collaboration)
- Italian Clinical Cooperative Oncology Group North East (Collaboration)
- The Royal Marsden Hospital London, United Kingdom (Collaboration)
- Kumamoto University (Collaboration)
- Interdisciplinary Group for Cancer Care Evaluation (GIVIO) (Collaboration)
- Beskids Oncology Centre (Collaboration)
- Doctor Negrin University Hospital of Gran Canaria (Collaboration)
- South Sweden Breast Cancer Group (Collaboration)
- Hospital Base of Osorno (Collaboration)
- Hospital Regional de Talca (Collaboration)
- Gualeguaychú Clinical and Oncology Centre (Collaboration)
- Kaplan Hospital (Collaboration)
- Hospital del Mar (Collaboration)
- Onkologikoa (Collaboration)
- Concepcion Diagnostic Centre (Collaboration)
- Jablonec nad Nisou Hospital (Collaboration)
- Hospital São Marcos (Collaboration)
- Ankara Oncology Hospital (Collaboration)
- Swiss Group for Cancer Clinical Research (SAKK) (Collaboration)
- Tokyo Cancer Institute Hospital (Collaboration)
- Toronto-Edmonton Breast Cancer Study Group (Collaboration)
- Hospital Regional de Antofagasta (Collaboration)
- Australian New Zealand Breast Cancer Trials Group (Collaboration)
- Ferdinando Veneziale Isernia Hospital (Collaboration)
- Rovereto Hospital (Collaboration)
- Virgen del Rocio University Hospital (Collaboration)
- National Kyushu Cancer Center (Collaboration)
- Hospital Doctor Luis Tisne (Collaboration)
- Daugavpils Oncological Hospital (Collaboration)
- National Medical Centre 20th November (Collaboration)
- Rosario Mastology Centre (Collaboration)
- Hospital Público Provincial De La Misericordia (Collaboration)
- Osaka City General Hospital (Collaboration)
- Hospital 12 de Octubre (Collaboration)
- Fox Chase Cancer Center (Collaboration)
- Città di Castello Hospital (Collaboration)
- Virgen Macarena University Hospital (Collaboration)
- Association for Cancer Surgery (BASO) (Collaboration)
- Groote Schuur Hospital (Collaboration)
- Sanatorium Park (Collaboration)
- University of Helsinki, Finland (Collaboration)
- National Institute for Cancer Research, Genoa (IST) (Istituto Nazionale per la Ricerca sul Cancro di Genova) (Collaboration)
- Liaoning Provincial People's Hospital (Collaboration)
- ARCOSEIN Group (Collaboration)
- University Hospital Donostia (Collaboration)
- Hospital General de Granollers (Collaboration)
- Spanish Breast Cancer Research Group (GEICAM) (Collaboration)
- Istanbul University (Collaboration)
- German Breast Cancer Study Group (BMFT) (Collaboration)
- Hospital Universitario Puerta de Hierro (Collaboration)
- Hospital d'Igualada (Collaboration)
- St Luke's Hospital, Dublin (Collaboration)
- Guy's Hospital (Collaboration)
- Lozano Blesa University Clinical Hospital (Collaboration)
- King Georges Medical University (Collaboration)
- University Hospital of Puerto Real (Collaboration)
- Oncocentro - Sociedade Civil Ltda, Fortaleza (Collaboration)
- Cancer and Leukemia Group B (Collaboration)
- Hospital Santa Maria (Collaboration)
- Queen Mary, University of London, United Kingdom (Collaboration)
- Piedmont Hematology Oncology Associates (Winston-Salem) (Collaboration)
- Hospital Virgen de la Salud (Collaboration)
- Hospital General De Manresa Heliport (Collaboration)
- Instituto Dr Estevez SA (Collaboration)
- Olomouc Teaching Hospital (Collaboration)
- Case Western Reserve University (Collaboration)
- Beth Israel Deaconess Medical Center (Collaboration)
- Base Hospital (Collaboration)
- Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) (Collaboration)
- The Mount Hospital (Collaboration)
- Ganzhou People's Hospital (Collaboration)
- Geelong Hospital (Collaboration)
- Hellenic Breast Surgical Society (HBSS) (Collaboration)
- Japan Clinical Oncology Group - Breast Cancer Study Group (Collaboration)
- ZOZ MSW Warminsko-Mazurskie Centrum Onkologii, Olsztyn, Poland (Collaboration)
- Pamela Youde Nethersole Eastern Hospital (Collaboration)
- Znojmo Hospital (Collaboration)
- Celestino Hernandez Robau Hospital in Santa Clara (Collaboration)
- Poznan University of Medical Sciences (Collaboration)
- Civil Hospital of Senigallia (Collaboration)
- Brazilian Institute of Cancer Control (IBCC) (Collaboration)
- Helios Hospital Berlin-Buch (Collaboration)
- Municipal Hospital No. 1, Novosibirsk (Collaboration)
- Nemocnice Liberec (Collaboration)
- Kawasaki Medical School (Collaboration)
- Sardinia Oncology Hospital A Businico (Collaboration)
- National Nagoya Hospital (Collaboration)
- Araújo Jorge Hospital (Collaboration)
- Japanese Foundation for Multidisciplinary Treatment of Cancer (Collaboration)
- University Hospital of the Canary Islands (Collaboration)
- Nagoya City University, Japan (Collaboration)
- Charles University, Czech Republic (Collaboration)
- Pilsen University Hospital (Collaboration)
- University of Pretoria (Collaboration)
- AstraZeneca plc (Collaboration)
- German Adjuvant Breast Cancer Group (GABG) (Collaboration)
- Leiden University Medical Center (Collaboration)
- Benedictine Hospital (Collaboration)
- Hospital Sótero del Río (Collaboration)
- University of Birmingham, United Kingdom (Collaboration)
- Academy of Sciences of the GDR (Collaboration)
- Italian Cooperative Chemo-Radio-Surgical Group (Collaboration)
- Hospital Argerich (Collaboration)
- Israel NSABC (Collaboration)
- Mútua Terrassa University Hospital (Collaboration)
- Hainan Provincial People's Hospital (Collaboration)
- Petrov Research Institute of Oncology (Collaboration)
- Oncology Center, Maria Sklodowska-Curie (Collaboration)
- SASIB International Trialists, Cape Town (Collaboration)
- Hospital San Juan de Dios (Collaboration)
- Arturo Lopez Perez Foundation (Collaboration)
- International TABLE Study Group (Collaboration)
- First People's Hospital of Chaohu (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- Heilongjiang Province Cancer Hospital (Collaboration)
- Hospital Regional Dr. Juan Noé (Collaboration)
- Panevezys Oncology Dispensary (Collaboration)
- Southampton Oncology Unit (Collaboration)
- Almirante Nef Naval Hospital (Collaboration)
- Cardiovascular Institute of Rosario (ICR) (Collaboration)
- Eastern Cooperative Oncology Group (ECOG) (Collaboration)
- University Hospital Plzen (Collaboration)
- Córdoba Private Institute of Radiotherapy (IPR) (Collaboration)
- Northwick Park Hospital (Collaboration)
- Marcianise Civil Hospital (Collaboration)
- Duran i Reynals Hospital (Collaboration)
- Hospital Roy H. Glover (Collaboration)
- Norwegian Breast Cancer Group (Collaboration)
- House Of Health Valdese (Collaboration)
- Central University Hospital of Liege (Collaboration)
- Hospital Interzonal General de Agudos “Eva Perón" (Collaboration)
- Karnatak Cancer Therapy & Research Institute (Collaboration)
- Clinical Hospital of the El Teniente Health Foundation (Collaboration)
- Humanitas Research Hospital (Collaboration)
- Mexican National Medical Centre (Collaboration)
- Bradford Royal Infirmary (Collaboration)
- Liepaja Oncological Hospital (Collaboration)
- Hospital Son Espases (Collaboration)
- Lower Silesian Oncology Center (Collaboration)
- Tel Aviv University, Israel (Collaboration)
- The National Institute of Oncology and Radiobiology (Collaboration)
- Helsinki Deaconess Medical Centre (Collaboration)
- Concepción Oncoradiology Centre (Collaboration)
- JICHI MEDICAL UNIVERSITY (Collaboration)
- Oncology Center of the Earth Lublin (Collaboration)
- European Organisation for Research and Treatment of Cancer (EORTC) (Collaboration)
- St George Hospital, Sydney (Collaboration)
- Uppsala-Orebro Breast Cancer Study Group, Sweden (Collaboration)
- Gustave-Roussy Institute (Collaboration)
- Danbury Hospital (Collaboration)
- Dutch Working Party for Autologous Bone Marrow Transplant in Solid Tumours (Collaboration)
- Innsbruck University, Austria (Collaboration)
- Královské Vinohrady University Hospital (Collaboration)
- Hospital Centre Etterbeek-Ixelles (Collaboration)
- Auckland Breast Cancer Study Group (ABCSG) (Collaboration)
- German Clinic of Santiago (Collaboration)
- Healthcare Consortium of Garraf (CSG) (Collaboration)
- University of Wuerzburg, Germany (Collaboration)
- Hospital de Mataro (Collaboration)
- Oncological Institute Romagnolo (Collaboration)
- Reñaca Clinic (Collaboration)
- Jawaharlal Nehru University, India (Collaboration)
- Gertsen's Institute of Oncology (Collaboration)
- University Hospital Puerta del Mar (Collaboration)
- Curie Institute Paris (Institut Curie) (Collaboration)
- WIM Klinika Onkologii (Collaboration)
- Frere Hospital (Collaboration)
- Toronto Princess Margaret Hospital (Collaboration)
- University Hospital Virgen de las Nieves, Granada (Collaboration)
- UK/ANZ DCIS (UK, Australia, and New Zealand Ductal Carcinoma in Situ) (Collaboration)
- Oita Prefectural Hospital (Collaboration)
- Hospital Regional de Rancagua (Collaboration)
- Institute Rotary Cancer Hospital (Collaboration)
- Hospital Intendente Gabriel Carrasco (Collaboration)
- National Cancer Institute of Bari (Collaboration)
- Birmingham Children's Hospital, Birmingham (Collaboration)
- North Sweden Breast Cancer Group, Umea (Collaboration)
- Hospital Teresa Herrera (Collaboration)
- Evanston Hospital (Collaboration)
- Multicentre Cancer Chemotherapy Study Group, London (Collaboration)
- Carabineros Hospital (Collaboration)
- General Hospital De Jerez De La Frontera (Collaboration)
- Chile National Cancer Institute (Instituto Nacional del Cáncer) (Collaboration)
- West German Study Group (WSG) (Collaboration)
- Gujarat Cancer & Research Institute (Collaboration)
- Hospital Durans I Reinals (Collaboration)
- Barzilai Medical Centre (Collaboration)
- Rabindranath Tagore Medical College (Collaboration)
- Ángel H Roffo Institute of Oncology (Collaboration)
- Alemán Hospital (Collaboration)
- MNJ Institute of Oncology (Collaboration)
- Kaohsiung Medical University (Collaboration)
- IKARUS Project (Incidence of Skeletal Related Events in Breast Cancer) (Collaboration)
- West Sweden Breast Cancer Study Group, Gothenburg (Collaboration)
- Our Lady of Candelaria University Hospital (Collaboration)
- Conrado Benitez Garcia Provincial Teaching Hospital Cancer (Collaboration)
- Hospital Jerez de la Frontera (Collaboration)
- Metaxas Memorial Cancer Hospital (Collaboration)
- Hosp Dr Luiz Antonio (Collaboration)
- Hospital de Sant Pau (Collaboration)
- Information Services Division (ISD) (Collaboration)
- University Hospital of Ourense (Collaboration)
- West of Scotland Breast Trial Group, Glasgow (Collaboration)
- University Hospitals Leuven (Collaboration)
- Maggiore Civil Hospital (Collaboration)
- Princess Margaret Cancer Centre (Collaboration)
- University of Naples (Collaboration)
- Montgomery Cancer Center (Collaboration)
- Hospital Universitario Insular de Gran Canaria (Collaboration)
- Institute of Oncology and Rehabilitation (Collaboration)
- Kutná Hora Hospital (Collaboration)
- University Hospital Son Espases (Collaboration)
- Santa Maria Clinic (Collaboration)
- Medical Oncology Centre of Rosebank (Collaboration)
- Vilnius University (Collaboration)
- Mayo Clinic (Collaboration)
- Hospital San Borja-Arriaran (Collaboration)
- Hospital Marcial Quiroga (Collaboration)
- Ospedale S Orsola- Malpighi, Bologna (Collaboration)
- Polish Ministry of Health (Collaboration)
- Oslo University Hospital (Collaboration)
- Unidad Oncológica Provincial, Pinar del Rio, Cuba (Collaboration)
- NZOZ Grupowa Praktyka Onkologiczna (Collaboration)
- San Lorenzo Medical Centre (Collaboration)
- Hospital Moinhos de Vento, Porto Alegre (Collaboration)
- Hospital General de Catalunya (Collaboration)
- Hospital Base of Valdivia (Collaboration)
- Fondazione Salvatore Maugeri (Collaboration)
- Royal Vinohrady Teaching Hospital (Collaboration)
- University of Wisconsin Madison, United States (Collaboration)
- Nolvadex Adjuvant Trial Organisation (Collaboration)
- North-Western British Surgeons, Manchester (Collaboration)
- Azienda Ospedaliera Spedali Civili di Brescia (Collaboration)
- Hospital Naval Puerto Belgrano (Collaboration)
- Naval Hospital of Talcahuano (Collaboration)
- University of Heidelberg, Germany (Collaboration)
- Oxford University Hospitals NHS Trust, United Kingdom (Collaboration)
- British Columbia Cancer Agency (BCCA) (Collaboration)
- Lismore Base Hospital (Collaboration)
- Istituto Nazionale per lo Studio e la Cura dei Tumoriit (Collaboration)
- University of Chicago, United States (Collaboration)
- Cathay General Hospital (Collaboration)
- Dr George Mukhari Hospital (Collaboration)
- Chinese Academy of Medical Sciences (CAMS) (Collaboration)
- Iris Sud Hospital (Collaboration)
- The Christie NHS Foundation Trust, Manchester (Collaboration)
- Bordet Institute (Collaboration)
- North Estonian Regional Cancer Centre (Collaboration)
- North-West Oncology Group (GONO), Italy (Collaboration)
- Ospedale Pelascini, Gravedona (Collaboration)
- National Health and Medical Research Council (Collaboration)
- General Teaching Hospital in Prague (Collaboration)
- Research Institute of Oncology, Minsk (Collaboration)
- Hospital Barros Luco Trudeau (Collaboration)
- Terrassa Health Consortium (Collaboration)
- PLA-81 Hosp, Nanjing (Collaboration)
- Sanatorium Plaza Rosario (Collaboration)
- Anglo-Celtic Cooperative Oncology Group (Collaboration)
- National Cancer Institute Egypt (Collaboration)
- Anhui Provincial People's Hospital (Collaboration)
- Xinxiang Central Hospital (Collaboration)
- Hospital Evaldo Foz (Collaboration)
- University of Texas at Houston (Collaboration)
- University of Chile (Collaboration)
- Regional Cancer Institute of Montpellier (Collaboration)
- National Surgical Adjuvant Breast and Bowel Project (NSABP) (Collaboration)
- University of the Witwatersrand, South Africa (Collaboration)
- Western Cancer Study Group (Collaboration)
- Hospital das Clínicas Samuel Libânio (Collaboration)
- Unicancer Breast Group, France (Collaboration)
- Liverpool Hospital (Collaboration)
- Hospital Regional Concepción (Collaboration)
- Provincial General Hospital of Santa Clara (Collaboration)
- Freeman Health System (Collaboration)
- Severo Ochoa University Hospital (Collaboration)
- Osaka National Hospital (Collaboration)
- Hospital Virgen del Camino (Collaboration)
- Hospital La Serena (Collaboration)
- Tres Arroyos Oncology Centre (Collaboration)
- Nottingham Uni Hospitals NHS Trust, United Kingdom (Collaboration)
- Shikoku Cancer Centre (Collaboration)
- University Hospital of Zagreb (Collaboration)
- Comprehensive Cancer Centre (Collaboration)
- Hospital General de Vic (Collaboration)
- Hospital Angeles Clinica Londres (Collaboration)
- Hiroshima University, Japan (Collaboration)
- Nemocnice Pardubice (Collaboration)
- Ludwig Maximilians University Munich (Collaboration)
- Chemo-N0 Trial (Collaboration)
- Hospital Rivadavia (Collaboration)
- Italian Oncology Group for Clinical Research (GOIRC) (Collaboration)
- Hacettepe University (Collaboration)
- Seeb (Collaboration)
- Susquehanna Health System (Collaboration)
- Erasmus MC (Collaboration)
- National Cancer Institute (NCI) (Collaboration)
- University Hospital Dr. Peset (Collaboration)
- Hospital Materno-Infantil (Collaboration)
- Changhua Christian Hospital (Collaboration)
- Nizams Institute of Medical Sciences (Collaboration)
- Hospital Italiano Garibaldi Rosario (Collaboration)
- Krakow Central Oncology Brance (Collaboration)
- Autonomous University of Barcelona (UAB) (Collaboration)
- Tampere University Hospital (Collaboration)
- University Hospital Brno (Collaboration)
- Hospital Regional de Temuco (Collaboration)
- Kaunas Medical University Hospital (Collaboration)
- Ocean Medical Center (Collaboration)
- Fujian Provincial Hospital (Collaboration)
- Sascatchewen Cancer Foundation (Collaboration)
- Keio University, Japan (Collaboration)
- St George's University of London, United Kingdom (Collaboration)
- Medical University of Vienna (Collaboration)
- Charing Cross Hospital (Collaboration)
- Jihlava Hospital (Collaboration)
- University Hospital Ghent (Collaboration)
- Bergonié Institute (Collaboration)
- Hospital Mater Dei (Collaboration)
- El-Minia Cancer Centre (Collaboration)
- Parma Hospital, Italy (Collaboration)
- Hospital de León (Collaboration)
- Hospital Regional Universitario de Málaga (Collaboration)
- Riga East University Hospital/Latvian Oncology Centre (Collaboration)
- Danish Breast Cancer Cooperative Group (DBCG) (Collaboration)
- South-East Sweden Breast Cancer Group (Collaboration)
- Hospital das Clinicas da UFMG (Collaboration)
- French Adjuvant Study Group (GEFA) (Collaboration)
- Portuguese Institute of Oncology, Coimbra (Collaboration)
- Mohandevi Oswal Cancer Hospital (Collaboration)
- Claudius Regaud Institute (Collaboration)
- Russian Academy of Medical Sciences (Collaboration)
- Szpital Specjalistyczny im.Rydygiera, Kraków, Poland (Collaboration)
- St Petersburg City Oncologicy Centre (Collaboration)
- Hospital of Cancer of Pernambuco (Collaboration)
- Southwest Oncology Group SWOG (Collaboration)
- National Cancer Center Hospital, Tokyo (Collaboration)
- Alexander Fleming Institute (Collaboration)
- Hospital Provincial de Rosario (Collaboration)
- Nemocnice Náchod (Collaboration)
- Box Hill Hospital (Collaboration)
- Saarland University, Germany (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- Government Medical College, Kottayam (Collaboration)
- Hainan Provincial Women and Children Hospital (Collaboration)
- Niigata Cancer Centre (Collaboration)
- Ospedale S Anna, Como (Collaboration)
- Ontario Clinical Oncology Group, Hamilton (Collaboration)
- Regional Hospital Sant Jaume de Calella (Collaboration)
- Sharett Institute of Oncology (Collaboration)
- Finnish Breast Cancer Group (Collaboration)
- University of Michigan, United States (Collaboration)
- René Huguenin Hospital (Collaboration)
- Hellenic Cooperative Oncology Group (HeCOG) (Collaboration)
- "Floraspe Renzetti" Hospital (Collaboration)
- University Hospital Ciudad de Jaén (Collaboration)
- Hospital General de Ciudad Real (Collaboration)
- Hospital Español (Collaboration)
- Glasgow Victoria Infirmary (Collaboration)
- Cancer Care Ontario (Collaboration)
- Regional Mammalogycal Centre, Yekaterinburg (Collaboration)
- Tunis Institut Salah Azaiz (Collaboration)
- Donostia Unibertsitate Ospitalea (Collaboration)
- Sanjay Gandhi Postgrad Inst Med Sciences (Collaboration)
- Marseille Biological Cancer Laboratory (Collaboration)
- Mexican National Cancer Institute (Collaboration)
- Belvedere Medical Corporation (Collaboration)
- Hospital Italiano de La Plata (Collaboration)
- Las Dalias Clinic (Collaboration)
- Salah Azaiez Institute (Collaboration)
- Government of Colombia (Collaboration)
- Leningrad Oncological Dispensary (Collaboration)
- Hospital Oncológico “Conrado Benítez” (Collaboration)
- Hubei Cancer Hospital (HBCH) (Collaboration)
- Spaarne Hospital Hoofddorp (Collaboration)
- Hospital Militar Central (Collaboration)
- Elim Hospital (Collaboration)
- Alcec - Concepcion del Uruguay (Collaboration)
- Netherlands Cancer Institute (Collaboration)
- National Cancer Institute, Cairo (Collaboration)
- Frederick Memorial Hosp, Frederick, US (Collaboration)
- Copenhagen Breast Cancer Trials (Collaboration)
- University Hospital La Paz (Collaboration)
- Centro De Enfermedades De La Mama Ltda (Collaboration)
- Hospital Militar de Santiago (Collaboration)
- Léon Bérard Center (Collaboration)
- German Breast Group (GBG) (Collaboration)
- San Martin Sanatorium (Collaboration)
- Trieste Oncology Centre (Collaboration)
- Provincial Mutuality Tucumán (Collaboration)
- Masaryk Memorial Cancer Institute (MMCI) (Collaboration)
- Coastal Cancer Centre (Collaboration)
- Hospital Sant Joan de Deu (Collaboration)
- Oncofrance (Collaboration)
- Kumamoto Central Hospital (Collaboration)
- Clinic Las Condes (Collaboration)
- Dubbo Base Hospital (Collaboration)
- U.S. Oncology, Houston (Collaboration)
- Cancer Centre of Excellence (Collaboration)
- Institute of Cancer Research UK (Collaboration)
- Hermanos Ameijeiras Hospital (Collaboration)
- University of Sheffield, United Kingdom (Collaboration)
- Hospital San Bernardo (Collaboration)
- Heinrich Heine University Düsseldorf (Collaboration)
- Belgian Adjuvant Breast Cancer Project (Collaboration)
- Cukurova University (Collaboration)
- Hospital Sant Jaume de Calella (Collaboration)
- Stockholm Breast Cancer Study Group, Sweden (Collaboration)
- Memorial Sloan Kettering Cancer Center (Collaboration)
- Masarykova nemocnice, usti nad Labem, Czech Republic (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- European Institute of Oncology (Collaboration)
- Oncology Group of Southern Italy (Collaboration)
- All India Institute of Medical Sciences (Collaboration)
- International Breast Cancer Study Group (IBCSG), Bern, Switzerland (Collaboration)
- Siauliai Onkologinis (Collaboration)
- Scandinavian Adjuvant Chemotherapy Study Group, Oslo (Collaboration)
- Hospital las Higueras (Collaboration)
- Evangelismos Hospital (Collaboration)
- Francois Baclesse Regional Centre for the Fight against Cancer (Collaboration)
Publications

Anderson GM
(2018)
Breast-Cancer Recurrence after Stopping Endocrine Therapy.
in The New England journal of medicine

Asselain B
(2018)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
in The Lancet Oncology

Aznar MC
(2018)
Exposure of the lungs in breast cancer radiotherapy: A systematic review of lung doses published 2010-2015.
in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology


Collaborative Group On Epidemiological Studies Of Ovarian Cancer
(2015)
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
in Lancet (London, England)

Collaborative Group On Hormonal Factors In Breast Cancer
(2012)
Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.
in The Lancet. Oncology

Davies C
(2017)
10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
in The Lancet


Davies C
(2013)
Tamoxifen therapy for patients with breast cancer - Authors' reply.
in Lancet (London, England)

Dowsett M
(2010)
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
in Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Guideline Title | NICE guidelines (CG80) Early and locally advanced breast cancer: Diagnosis and treatment |
Description | NICE Guideline on the management of early breast cancer |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Impact | EBCTCG is referenced 20 times in the current NICE guideline on the management of early breast cancer. |
URL | http://www.nice.org.uk/guidance/cg80 |
Guideline Title | Scottish Intelligence Guideline Network (SIGN) guideline on treatment of primary breast cancer (SIGN 134) |
Description | Scottish Intelligence Guideline Network (SIGN) guideline on treatment of primary breast cancer (SIGN 134) |
Geographic Reach | National |
Policy Influence Type | Citation in clinical guidelines |
Impact | EBCTCG is referenced 14 times in the SIGN guideline on the treatment of primary breast cancer |
URL | http://www.sign.ac.uk/guidelines/fulltext/134/index.html |
Guideline Title | US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Breast Cancer |
Description | US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Breast Cancer |
Geographic Reach | North America |
Policy Influence Type | Citation in clinical guidelines |
Impact | EBCTCG is referenced 6 times in the US National Comprehensive Cancer Network (NCCN) guideline on breast cancer. |
URL | http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast |
Guideline Title | US National Institutes of Health (NIH) guideline on breast cancer treatment for health professionals |
Description | US National Institutes of Health (NIH) guideline on breast cancer treatment for health professionals |
Geographic Reach | North America |
Policy Influence Type | Citation in clinical guidelines |
Impact | EBCTCG is cited in relation to the different aspects of treatment for early breast cancer (i.e. local therapies and systemic therapies). |
URL | http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional |
Description | Research grant (ATLAS trial) |
Amount | £508,000 (GBP) |
Organisation | AstraZeneca |
Sector | Private |
Country | United Kingdom |
Start | 04/2003 |
End | 12/2015 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | "Floraspe Renzetti" Hospital |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | "Floraspe Renzetti" Hospital |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Alcec - Concepcion del Uruguay |
Country | Argentina |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Alemán Hospital |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Alexander Fleming Institute |
Country | Argentina |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Alexander Fleming Institute |
Country | Argentina |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | All India Institute of Medical Sciences |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Almirante Nef Naval Hospital |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Almirante Nef Naval Hospital |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Anhui Provincial People's Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Ankara Oncology Hospital |
Country | Turkey |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Araújo Jorge Hospital |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Arturo Lopez Perez Foundation |
Country | Chile |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Autonomous University of Barcelona (UAB) |
Department | Parc Taulí Health Corporation |
Country | Spain |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Azienda Ospedaliera Spedali Civili di Brescia |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Barzilai Medical Centre |
Country | Israel |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Base Hospital |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Base Hospital |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Belvedere Medical Corporation |
Country | United States |
Sector | Private |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Benedictine Hospital |
Country | United States |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Beskids Oncology Centre |
Country | Poland |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Beth Israel Deaconess Medical Center |
Country | United States |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Bordet Institute |
Country | Belgium |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Box Hill Hospital |
Country | Australia |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Brazilian Institute of Cancer Control (IBCC) |
Country | Brazil |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Brazilian Institute of Cancer Control (IBCC) |
Country | Brazil |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Cancer Centre of Excellence |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Carabineros Hospital |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Cardiovascular Institute of Rosario (ICR) |
Country | Argentina |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Cathay General Hospital |
Country | Taiwan, Province of China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Celestino Hernandez Robau Hospital in Santa Clara |
Country | Cuba |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Central University Hospital of Liege |
Country | Belgium |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Centro De Enfermedades De La Mama Ltda |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Changhua Christian Hospital |
Country | Taiwan, Province of China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Chile National Cancer Institute (Instituto Nacional del Cáncer) |
Country | Chile |
Sector | Public |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Chinese Academy of Medical Sciences (CAMS) |
Country | China |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Città di Castello Hospital |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Civil Hospital of Senigallia |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Civil Hospital of Senigallia |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Clinic Las Condes |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Clinical Hospital of the El Teniente Health Foundation |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Clinical Hospital of the El Teniente Health Foundation |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Coastal Cancer Centre |
Country | United States |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Concepcion Diagnostic Centre |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Concepción Oncoradiology Centre |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Conrado Benitez Garcia Provincial Teaching Hospital Cancer |
Country | Cuba |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Cukurova University |
Department | Balcali Hospital |
Country | Turkey |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Córdoba Private Institute of Radiotherapy (IPR) |
Country | Argentina |
Sector | Private |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Danbury Hospital |
Country | United States |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Daugavpils Oncological Hospital |
Country | Latvia |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Doctor Negrin University Hospital of Gran Canaria |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Donostia Unibertsitate Ospitalea |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Dr George Mukhari Hospital |
Country | South Africa |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Dubbo Base Hospital |
Country | Australia |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Duran i Reynals Hospital |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Edith Wolfson Medical Center |
Country | Israel |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | El-Minia Cancer Centre |
Country | Egypt |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Espases University Hospital |
Country | Spain |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Evangelismos Hospital |
Country | Greece |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Evangelismos Hospital |
Country | Greece |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Ferdinando Veneziale Isernia Hospital |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | First People's Hospital of Chaohu |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Frederick Memorial Hosp, Frederick, US |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Freeman Health System |
Country | United States |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Frere Hospital |
Country | South Africa |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Frere Hospital |
Country | South Africa |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Fujian Provincial Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Ganzhou People's Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Ganzhou People's Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Geelong Hospital |
Country | Australia |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | General Hospital De Jerez De La Frontera |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | General Teaching Hospital in Prague |
Country | Czech Republic |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | German Clinic of Santiago |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Gertsen Moscow Research Oncology Institute |
Country | Russian Federation |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Gertsen's Institute of Oncology |
Country | Russian Federation |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Government Medical College, Kottayam |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Government Medical College, Kottayam |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Government of Colombia |
Department | National Cancer Institute |
Country | Colombia |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Groote Schuur Hospital |
Country | South Africa |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Groote Schuur Hospital |
Country | South Africa |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Gualeguaychú Clinical and Oncology Centre |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Gujarat Cancer & Research Institute |
Country | India |
Sector | Charity/Non Profit |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hacettepe University |
Department | Hacettepe University Cancer Institute |
Country | Turkey |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hacettepe University |
Country | Turkey |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hainan Provincial People's Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hainan Provincial Women and Children Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Healthcare Consortium of Garraf (CSG) |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Heilongjiang Province Cancer Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Heilongjiang Province Cancer Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hermanos Ameijeiras Hospital |
Country | Cuba |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hermanos Ameijeiras Hospital |
Country | Cuba |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hiroshima University |
Department | Research Institute for Nuclear Medicine and Biology |
Country | Japan |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hosp Dr Luiz Antonio |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hosp Dr Luiz Antonio |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital 12 de Octubre |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital 12 de Octubre |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Amstelland |
Country | Netherlands |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Angeles Clinica Londres |
Country | Mexico |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Argerich |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Argerich |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Barros Luco Trudeau |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Barros Luco Trudeau |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Base of Osorno |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Base of Valdivia |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Centre Etterbeek-Ixelles |
Country | Belgium |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Comarcal de Blanes |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Comarcal de Blanes |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Dipreca |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Dipreca |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Doctor Luis Tisne |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Durans I Reinals |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Escuela Eva Perón |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Español |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Evaldo Foz |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Evaldo Foz |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General De Manresa Heliport |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General De Manresa Heliport |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General San Jorge of Huesca |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General San Jorge of Huesca |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General de Catalunya |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General de Ciudad Real |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General de Ciudad Real |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General de Granollers |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General de Granollers |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General de Vic |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital General de Vic |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Intendente Gabriel Carrasco |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Interzonal General de Agudos “Eva Perón" |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Interzonal General de Agudos “Eva Perón" |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Italiano Garibaldi Rosario |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Italiano de La Plata |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Italiano de La Plata |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Jerez de la Frontera |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital La Serena |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital La Serena |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Marcial Quiroga |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Marcial Quiroga |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Mater Dei |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Mater Dei |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Materno-Infantil |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Militar Central |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Militar de Santiago |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Militar de Santiago |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Moinhos de Vento, Porto Alegre |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Moinhos de Vento, Porto Alegre |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Napoleão Laureano, Joao Pessoa |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Napoleão Laureano, Joao Pessoa |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Naval Puerto Belgrano |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Oncológico “Conrado Benítez” |
Country | Cuba |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Provincial de Rosario |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Público Provincial De La Misericordia |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Público Provincial De La Misericordia |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional Concepción |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional Concepción |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional Dr. Juan Noé |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional Dr. Juan Noé |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional Universitario de Málaga |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional Universitario de Málaga |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional de Antofagasta |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional de Antofagasta |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional de Rancagua |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional de Rancagua |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional de Talca |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional de Talca |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Regional de Temuco |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Rivadavia |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Roy H. Glover |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital San Bernardo |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital San Borja-Arriaran |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital San Borja-Arriaran |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital San Juan de Dios |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital San Juan de Dios |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Sant Jaume de Calella |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Sant Joan de Deu |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Santa Maria |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Santa Maria |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Son Espases |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital São Marcos |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital São Marcos |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Sótero del Río |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Sótero del Río |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Teresa Herrera |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Universitario De La Princesa |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Universitario De La Princesa |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Universitario Insular de Gran Canaria |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Universitario Puerta de Hierro |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Virgen de la Salud |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Virgen de la Salud |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Virgen del Camino |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital Virgen del Camino |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital d'Igualada |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital d'Igualada |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital das Clinicas da UFMG |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital das Clinicas da UFMG |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital das Clínicas Samuel Libânio |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital das Clínicas Samuel Libânio |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital de León |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital de León |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital de Mataro |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital de Mataro |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital de Sant Pau |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital de Sant Pau |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital del Mar |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital del Mar |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital del Salvador |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital del Salvador |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital las Higueras |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hospital of Cancer of Pernambuco |
Country | Brazil |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | House Of Health Valdese |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | House Of Health Valdese |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Hubei Cancer Hospital (HBCH) |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | IKARUS Project (Incidence of Skeletal Related Events in Breast Cancer) |
Country | Czech Republic |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Inner Mongolia Medical College Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Institute Rotary Cancer Hospital |
Country | India |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Institute Rotary Cancer Hospital |
Country | India |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Institute of Oncology and Rehabilitation |
Country | Czech Republic |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Instituto Dr Estevez SA |
Country | Argentina |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Iris Sud Hospital |
Country | Belgium |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Istanbul University |
Department | Faculty of Medicine |
Country | Turkey |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Istanbul University |
Department | Institute of Oncology |
Country | Turkey |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Istanbul University |
Department | Institute of Oncology |
Country | Turkey |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Jablonec nad Nisou Hospital |
Country | Czech Republic |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Jawaharlal Nehru University, India |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Jiangxi Province Cancer Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Jichi Medical University |
Country | Japan |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Jihlava Hospital |
Country | Czech Republic |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Kaohsiung Medical University |
Country | Taiwan, Province of China |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Kaohsiung Medical University |
Country | Taiwan, Province of China |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Kaplan Hospital |
Country | Israel |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Karnatak Cancer Therapy & Research Institute |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Karnatak Cancer Therapy & Research Institute |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Kaunas Medical University Hospital |
Country | Lithuania |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Keio University |
Country | Japan |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | King George's Medical University |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Krakow Central Oncology Brance |
Country | Poland |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Královské Vinohrady University Hospital |
Country | Czech Republic |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Kumamoto Central Hospital |
Country | Japan |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Kutná Hora Hospital |
Country | Czech Republic |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Las Dalias Clinic |
Country | Chile |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Las Higueras Hospital |
Country | Chile |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Leningrad Oncological Dispensary |
Country | Russian Federation |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Liaoning Provincial People's Hospital |
Country | China |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Liepaja Oncological Hospital |
Country | Latvia |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Lismore Base Hospital |
Country | Australia |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Lismore Base Hospital |
Country | Australia |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Liverpool Hospital |
Country | Australia |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Lower Silesian Oncology Center |
Country | Poland |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Lozano Blesa University Clinical Hospital |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Lozano Blesa University Clinical Hospital |
Country | Spain |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | MNJ Institute of Oncology |
Country | India |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Madras Cancer Institute (WIA), Chennai |
Country | India |
Sector | Academic/University |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Maggiore Civil Hospital |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Marcianise Civil Hospital |
Country | Italy |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Maria Curie Provincial Teaching Cancer Hospital |
Country | Cuba |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Masaryk Memorial Cancer Institute (MMCI) |
Country | Czech Republic |
Sector | Hospitals |
PI Contribution | ATLAS is coordinated by CTSU and has randomised over 15,000 women, making it the largest ever trial of the treatment of breast cancer. |
Collaborator Contribution | Local collaborating hospitals are responsible for the recruitment and follow-up of their patients who participate in ATLAS. |
Impact | Although follow-up continues, interim findings from ATLAS have clearly shown that continuing tamoxifen treatment for 10 years instead of stopping after only 5 years had little effect on either recurrence rates or death rates during the period 5-9 years after diagnosis. However, women allocated to continue tamoxifen had 25% lower recurrence rate and 29% lower breast cancer mortality during years 10-14 than women allocated to stop after only 5 years. Tamoxifen is still widely used, particularly for pre-menopausal women and the ATLAS results are likely to change treatment guidelines, doubling the recommended tamoxifen duration to 10 years. |
Start Year | 2006 |
Description | Adjuvant Tamoxifen Longer Against Shorter (ATLAS) Trial |
Organisation | Masaryk Memorial Cancer Institute (MMCI) |
Country | Czech Republic |